Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Molecular cancer therapeutics - 1 Apr 2009

Yeh Jen Jen, Routh Elizabeth D, Rubinas Tara, Peacock Janie, Martin Timothy D, Shen Xiang Jun, Sandler Robert S, Kim Hong Jin, Keku Temitope O, Der Channing J

Abstract excerpt

Phase II clinical trials of mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitors are ongoing and ERK1/2 activation is frequently used as a biomarker. In light of the mutational activation of BRAF and KRAS in colorectal cancer, inhibitors of the Raf-MEK-ERK mitogen-activated protein kinase are anticipated to be promising. Previous studies in pancreatic cancer have found...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Butadienes
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase 1

Share to MAP Kinase Kinase 2

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Nitriles

Share to Tissue Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 19372556
DOI: 10.1158/1535-7163.MCT-08-0972
PMCID: PMC2729756

Genes

BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.PMID 19372556Read ↗

MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.Semantic proximity Read ↗

KRAS mutation-independent downregulation of MAPK/PI3K signaling in colorectal cancer.Semantic proximity Read ↗

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.Semantic proximity Read ↗

High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cellsSemantic proximity Read ↗

Novel mitogen-activated protein kinase kinase inhibitors.Semantic proximity Read ↗

Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.Semantic proximity Read ↗

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.Semantic proximity Read ↗

The association between ERK inhibitor sensitivity and molecular characteristics in colorectal cancer.Semantic proximity Read ↗

Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epitheliumSemantic proximity Read ↗

Clinical-pathological correlation of K-Ras mutation and ERK phosphorylation in colorectal cancer.Semantic proximity Read ↗

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.Semantic proximity Read ↗

Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.